{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:39:57Z","timestamp":1778503197527,"version":"3.51.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1677,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002879","name":"Canadian Institute of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018911","name":"University of Alberta Hospital Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aims to assess long-term changes in left ventricular ejection fraction (LVEF) together with echocardiographic markers of cardiac remodelling and their association with prognosis and patient-reported quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of serial echocardiograms performed between January 2009 and December 2019 in 1089 patients (median age 63 years, 71.0% men) enrolled in the Mazankowski Heart Function Clinic Registry who had at least two echocardiograms separated by \u226512 months. We classified the patients into four subgroups by their baseline and LVEF trajectories: persistent heart failure with reduced ejection fraction (persistent HFrEF, n = 364), recovered ejection fraction (HFrecEF, n = 325), transient recovery in ejection fraction (HFtrecEF, n = 117), and preserved ejection fraction (HFpEF, n = 283); 4490 echocardiograms were included in the present analysis, with 4.1 \u00b1 1.8 echocardiograms available per patient during follow-up. Reductions in echocardiographic markers of cardiac remodelling, including LVIDd [adjusted odds ratio (aOR): 2.22, 95% confidence interval (CI) 1.75\u20132.86], LVIDs (aOR: 2.44, 95% CI 2.00\u20132.94), left ventricular mass index (aOR: 1.15, 95% CI 1.09\u20131.22), E\/e\u2032 ratio (aOR: 1.15, 95% CI 1.02\u20131.30), left atrial volume index (aOR: 1.10, 95% CI 1.03\u20131.16), along with an increase in the maximum recommended daily dose of renin-angiotensin system inhibitors (aOR: 1.04, 95% CI 1.01\u20131.07) and mineralocorticoid-receptor antagonists (aOR: 1.06, 95% CI 1.01\u20131.11) at 2 years, strongly predicted the HFrecEF classification, which was further sustained at 5 years of follow-up. However, changes in these parameters were mostly absent in patients experiencing only a transient recovery in LVEF (HFtrecEF), closely resembling patients with persistent HFrEF. In the multivariable analysis, HFrecEF patients had lower risk of all-cause mortality alone [adjusted hazard ratio (aHR): 0.46, 95% CI 0.23\u20130.93], and composite all-cause (aHR: 0.59, 95% CI 0.49\u20130.73), cardiovascular (aHR: 0.47, 95% CI 0.36\u20130.61), and heart failure (aHR: 0.50, 95% CI 0.35\u20130.70) related hospitalizations with mortality than patients with persistent HFrEF. QoL assessed through the shortened Kansas City Cardiomyopathy Questionnaire-12 at the end of follow-up was greater in patients with HFrecEF by 5.2, 12.4, and 9.4 points than persistent HFrEF, HFtrecEF, and HFpEF, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with HFrecEF experienced progressive normalization in echocardiographic markers of cardiac remodelling characterized by reductions in left ventricular dimensions and mass in tandem with reductions in left atrial volume and E\/e\u2032 ratio, which is associated with better prognosis and QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13417","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T07:45:33Z","timestamp":1621323933000},"page":"3106-3118","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cardiac Reverse Remodelling and Health Status in Patients with Chronic Heart Failure"],"prefix":"10.1093","volume":"8","author":[{"given":"Kaiming","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Alberta, T6G 2S2 ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Youngson","sequence":"additional","affiliation":[{"name":"Alberta Strategy for Patient Oriented Research (SPOR) Unit, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Bakal","sequence":"additional","affiliation":[{"name":"Alberta Strategy for Patient Oriented Research (SPOR) Unit, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jissy","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Alberta, T6G 2S2 ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finlay A.","family":"McAlister","sequence":"additional","affiliation":[{"name":"Mazankowski Alberta Heart Institute, University of Alberta , Edmonton, Alberta ,","place":["Canada"]},{"name":"Alberta Strategy for Patient Oriented Research (SPOR) Unit, University of Alberta , Edmonton, Alberta ,","place":["Canada"]},{"name":"Division of General Internal Medicine, Department of Medicine, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Alberta , Edmonton, Alberta, T6G 2S2 ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"2026012114211853500_ehf213417-bib-0001","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114211853500_ehf213417-bib-0002","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehz233","article-title":"Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study","volume":"40","author":"Ghimire","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114211853500_ehf213417-bib-0003","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0004","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lupon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0005","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"2026012114211853500_ehf213417-bib-0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"2026012114211853500_ehf213417-bib-0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/eurjhf\/hfq182","article-title":"Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy","volume":"13","author":"Foley","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0009","first-page":"1","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026012114211853500_ehf213417-bib-0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lupon","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0012","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114211853500_ehf213417-bib-0013","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12265-019-09919-9","article-title":"Heterogeneous outcomes of heart failure with better ejection fraction","volume":"13","author":"Van Kirk","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"2026012114211853500_ehf213417-bib-0014","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012114211853500_ehf213417-bib-0015","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114211853500_ehf213417-bib-0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006939","article-title":"Elevated angiotensin 1-7\/angiotensin II ratio predicts favorable outcomes in patients with heart failure","volume":"13","author":"Wang","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0017","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1475-6773.2007.00822.x","article-title":"Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database","volume":"43","author":"Quan","year":"2008","journal-title":"Health Serv Res"},{"key":"2026012114211853500_ehf213417-bib-0018","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/pds.4861","article-title":"Validation of drug prescription records for senior patients in Alberta's Tomorrow Project: assessing agreement between two population-level administrative pharmaceutical databases in Alberta, Canada","volume":"28","author":"Ye","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012114211853500_ehf213417-bib-0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ehf2.12586","article-title":"Heart failure with mid-range ejection fraction: pro and cons of the new classification of heart failure by European Society of Cardiology guidelines","volume":"7","author":"Branca","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0020","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2026012114211853500_ehf213417-bib-0021","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0022","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijcard.2015.02.019","article-title":"Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score","volume":"184","author":"Lupon","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0023","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jchf.2017.07.011","article-title":"Effect of sex on reverse remodeling in chronic systolic heart failure","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0024","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrcardio.2011.154","article-title":"Cardiac remodeling at the population level\u2014risk factors, screening, and outcomes","volume":"8","author":"Gjesdal","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0025","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.1057","article-title":"Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF","author":"Halliday","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0026","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114211853500_ehf213417-bib-0027","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0028","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0029","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2015.12.011","article-title":"Variable contribution of heart failure to quality of life in ambulatory heart failure with reduced, better, or preserved ejection fraction","volume":"4","author":"Joyce","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017278","article-title":"Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure","volume":"9","author":"Sepehrvand","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114211853500_ehf213417-bib-0031","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0032","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114211853500_ehf213417-bib-0033","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment","volume":"22","author":"Nauta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114211853500_ehf213417-bib-0034","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003788","article-title":"Abnormal global longitudinal strain predicts future deterioration of left ventricular function in heart failure patients with a recovered left ventricular ejection fraction","volume":"10","author":"Adamo","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/3106\/65568773\/eschf_8_4_3106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/3106\/65568773\/eschf_8_4_3106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:26:07Z","timestamp":1769023567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/4\/3106\/8344429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,18]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13417","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"2021-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}